Posted in Antibodies, Assay Kits, Biology Cells, cDNA, Clia Kits, Devices, DNA, Equipments, Exosomes, Gels, Isotypes, Medium & Serums, NATtrol, Panel, Particles, Reagents, Recombinant Proteins, Ria Kits, RNA, Test Kits
Human Cytomegalovirus Induces the Expression of the AMPKa2 Subunit to Drive Glycolytic Activation and Support Productive Viral Infection
The human cytomegalovirus infection (HCMV) modulates cellular metabolism to support viral replication. Kinase Kinase Kinase Calcium / Calmodulin (CAMKK) and Protein activated amp (AMPK) regulates metabolic activation and has been found important for successful HCMV infections. Here, we explore the specific contributions of camkk isoforms and ampk subunit isoforms to make HCMV infection. Our results show that various ISOFORM camkk and AMPK contribute to infection in a unique way.
For example, Camkk1 is important for HCMV infection in low infection multiplicity, but can be used for AMPK activation during the earliest infection, which is suggested by our data more dependent on camkk2. Our results also show that HCMV specifically induces the expression of catalytic subunit ampka2 non-ubiquitous, which is found important for glycolytic activation mediated by HCMV and high titers infections. Furthermore, we found that glycolytic activation mediated ampk was important for infection, as an excessive expression of glut4, high-capacity glucose transporter, some saved viral replication in the face of the inhibition of Ampk.
Collectively, our data shows that HCMV infection selectively induces specific metabolic regulation kinase expression, relying on their activities to support glycolytic activation and productive infection. The important virus is a mandatory parasite to provide energy and molecular building blocks to the masses to produce a descendant of the infectious virus. The process that regulates the modulation of cellular resource viruses has emerged as critical for successful infections.
Here, we find that HCMV depends on two kinase isoforms to support infection, camkk1 and ampka2. We found that HCMV specifically induces ampka2 subunit expression to induce metabolic activation and encourage strong viral replication. These results indicate that HCMV has evolved a mechanism to target certain metabolic regulatory kinase subunits to support productive infections, thus providing insight into how HCMV hijacked cellular metabolism for replication, and explained the vulnerability of potential virus therapy.
Cytomegalovirus cervical reactivation, cytokine, and spontaneous premature birth in Kenyan women
Activation of cytomegalovirus genital reactivation (CMV) is common during the third trimester of pregnancy. We hypothesize, cervical CMV shedding can increase the risk of spontaneous premature birth (SPTB) through the release of inflammatory cytokines in the cervix. We conducted a nesting case control analysis to determine the relationship between shedding CMV and SPTB using data and samples from prospective cohort studies in West Kenya. Women delivered between 28 + 0 and 33 + 6 weeks of pregnancy are adjusted to the gestational age on the collection of samples to control delivered ≥37 + 0 weeks.
The Level of CMV DNA and Interleukin (IL) -1 Beta (β), IL-6, IL-8, and Necrosis Factor-Alpha (TNF-α) tumors are measured in the servix. We use conditional logistic regression to assess the relationship between shedding cmv, cervical cytokine levels, and SPTB. Among the 86 cases and 86 suitable controls, cmv cervical levels are not significantly related to the SPTB (Odds Ratio [or] = 1.23, 95% trust interval [CI] 0.59-2.56), but significantly associated With higher IL-6 cervical levels. (β = 0.15, 95% CI 0.02-0.29) and TNF-α (β = 0.14, 95% CI 0.01-0.27). In univariate analysis, higher SPTB opportunities are associated with higher cervical IL-6 levels (or = 1.54, 95% CI 1.00-2.38), but not with other cervical cytokines. In this Kenyan women’s cohort, we did not find a significant relationship between cervical and SPTB shedding before 34 weeks.
Letermovir prophylaxis is effective in preventing reactivation of cytomegalovirus after alogenic hematopoietic cell transplantation: real single world data data
Morbidity and mortality after alogenic hematopoietic cell transplants (ALLOHCT) are still basically influenced by Cytomegalovirus (CMV) reactivation. We evaluate 80 seropositive patients transplanted in a row between March 2018 and March 2019 who received the prophylaxis of the Letermovir (leave) from engraftment to day +100 and retrospectively compare it with 80 patients without allowing allograft between January 2017 and March 2018.
The end point of research This is a cumulative incidence (CI) Clinically significant CMV infection (CS-CMVI) defined as CMV reactivation which demands preemptive treatment or CMV disease. With 14% CI CS-CMVI on the day +100 (11 events) significantly lower in let the cohort compared to the control group (33 events, 41%; HR 0.29; p <0.001). While therapy with Foscarnet can be fully avoided in the Group Leave, 7 out of 80 patients in the control cohort receiving Foscarnet, producing 151 extra patients for foscarnet (p = 0.002). The overall survival of one year is 72% on the control arm vs. 84% in the arms (HR 0.75 [95% CI 0.43-1.30]; P <0.306). This study confirms the efficacy and security let’s for the CS-CMVI prophylaxis after ALLOHCT in real-world settings, resulting in significant patient benefits by reducing hospitalization needs and exposure to antivirus drugs that are potentially toxic for the treatment of CMV reactivation.

Micrornas screening and validation and targets expressly expressed in hypertensive mice caused by cytomegalovirus infection
Introduction Some studies have suggested the relationship between Cytomegalovirus (CMV) infection and essential hypertension (eh). Micrornas (MIRNAS) plays an important role in developing EH by regulating specific target gene expression. However, a few are known about the role of MIRNA in uh induced by CMV. In this study, we compare the profile of Mirna’s expressions from samples from normal and murine cytomegalovirus (MCMV) -Infected C57BL / 6 mice using high-throughput sequencing analysis.
The method we collect thoracic aortic, heart tissue, and peripheral blood of twenty normal mice and twenty mice infected with MCMV. We identify Mirna which is expressly expressed in peripheral blood samples and predicts their target genes using bioinformatics tools. We then experimentally validated them using QRT-PCR and target genes with a double luciferase gene test test. The results we found 118 expressed by MIRNAs, including 9 MIRNAs was identified as potential hypertensive regulators induced by MCMV infection. We then validated the expression of two MIRAS candidates, MMU-MIR-1929-3P and MCMV-MIR-M01-4-5P, using QRT-PCR.
FBXO17 Antibody - N-terminal region |
MBS3217540-01mL |
MyBiosource |
0.1mL |
EUR 455 |
FBXO17 Antibody - N-terminal region |
MBS3217540-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1995 |
F-Box Protein 17 (FBXO17) Antibody |
abx233038-100g |
Abbexa |
100 µg |
EUR 350 |
F-Box Protein 17 (FBXO17) Antibody |
abx233038-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
ARP67585_P050-25UL - FBXO17 Antibody - N-terminal region |
ARP67585_P050-25UL |
Aviva Systems Biology |
25ul |
EUR 99 |
|
ARP67585_P050 - FBXO17 Antibody - N-terminal region (ARP67585_P050) |
ARP67585_P050 |
Aviva Systems Biology |
100ul |
EUR 389 |
|
FBXO17 |
CSB-CL853409HU |
Cusabio |
10 μg plasmid + 200μl Glycerol |
Ask for price |
FBXO17 |
MBS8563971-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
FBXO17 |
MBS8563971-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
FBXO17 |
MBS8563971-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
FBXO17 |
MBS8563971-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
Rat FBXO17 siRNA |
20-abx916592 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
FBXO17 siRNA (Rat) |
MBS8219173-15nmol |
MyBiosource |
15nmol |
EUR 405 |
FBXO17 siRNA (Rat) |
MBS8219173-30nmol |
MyBiosource |
30nmol |
EUR 565 |
FBXO17 siRNA (Rat) |
MBS8219173-5x30nmol |
MyBiosource |
5x30nmol |
EUR 2450 |
FBXO17 cDNA Clone |
MBS1275537-001mgPlasmid02mLGlycerolStock |
MyBiosource |
0.01mgPlasmid+0.2mLGlycerol-Stock |
EUR 300 |
FBXO17 cDNA Clone |
MBS1275537-5x001mgPlasmid5x02mLGlycerolStock |
MyBiosource |
5x0.01mgPlasmid+5x0.2mLGlycerol-Stock |
EUR 1300 |
Mouse FBXO17 siRNA |
20-abx916593 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Human FBXO17 siRNA |
20-abx901910 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
FBXO17 siRNA (Mouse) |
MBS8203339-15nmol |
MyBiosource |
15nmol |
EUR 405 |
FBXO17 siRNA (Mouse) |
MBS8203339-30nmol |
MyBiosource |
30nmol |
EUR 565 |
FBXO17 siRNA (Mouse) |
MBS8203339-5x30nmol |
MyBiosource |
5x30nmol |
EUR 2450 |
FBXO17 siRNA (Human) |
MBS8215045-15nmol |
MyBiosource |
15nmol |
EUR 405 |
FBXO17 siRNA (Human) |
MBS8215045-30nmol |
MyBiosource |
30nmol |
EUR 565 |
FBXO17 siRNA (Human) |
MBS8215045-5x30nmol |
MyBiosource |
5x30nmol |
EUR 2450 |
FBXO17 cloning plasmid |
CSB-CL853409HU-10ug |
Cusabio |
10ug |
EUR 411.6 |
|
Description: A cloning plasmid for the FBXO17 gene. |
FBXO17 Blocking Peptide |
DF13006-BP |
Affbiotech |
1mg |
EUR 234 |
FBXO17 Blocking Peptide |
MBS9621710-1mg |
MyBiosource |
1mg |
EUR 380 |
FBXO17 Blocking Peptide |
MBS9621710-5x1mg |
MyBiosource |
5x1mg |
EUR 1650 |
Recombinant Human FBXO17 |
MBS7615987-005mg |
MyBiosource |
0.05mg |
EUR 405 |
Recombinant Human FBXO17 |
MBS7615987-02mg |
MyBiosource |
0.2mg |
EUR 760 |
Recombinant Human FBXO17 |
MBS7615987-1mg |
MyBiosource |
1mg |
EUR 2175 |
Recombinant Human FBXO17 |
MBS7615987-5x1mg |
MyBiosource |
5x1mg |
EUR 8410 |
FBXO17 (untagged)-Human F-box protein 17 (FBXO17), transcript variant 1 |
SC310570 |
Origene Technologies GmbH |
10 µg |
Ask for price |
FBXO17 (untagged)-Human F-box protein 17 (FBXO17), transcript variant 2 |
SC323757 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Rat FBXO17 shRNA Plasmid |
20-abx988576 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Mouse FBXO17 shRNA Plasmid |
20-abx974104 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Human FBXO17 shRNA Plasmid |
20-abx964438 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Human FBXO17 Protein Lysate |
MBS8411631-002mg |
MyBiosource |
0.02mg |
EUR 365 |
Human FBXO17 Protein Lysate |
MBS8411631-5x002mg |
MyBiosource |
5x0.02mg |
EUR 1410 |
FBXO17 Recombinant Protein (Rat) |
RP200984 |
ABM |
100 ug |
Ask for price |
FBXO17 (GFP-tagged) - Human F-box protein 17 (FBXO17), transcript variant 2 |
RG202158 |
Origene Technologies GmbH |
10 µg |
Ask for price |
FBXO17 (GFP-tagged) - Human F-box protein 17 (FBXO17), transcript variant 1 |
RG222996 |
Origene Technologies GmbH |
10 µg |
Ask for price |
FBXO17 Recombinant Protein (Human) |
RP011875 |
ABM |
100 ug |
Ask for price |
FBXO17 Recombinant Protein (Mouse) |
RP133955 |
ABM |
100 ug |
Ask for price |
anti- FBXO18 antibody |
FNab03039 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against FBXO18 |
anti- FBXO22 antibody |
FNab03041 |
FN Test |
100µg |
EUR 702 |
|
Description: Antibody raised against FBXO22 |
anti- FBXO28 antibody |
FNab03042 |
FN Test |
100µg |
EUR 702 |
|
Description: Antibody raised against FBXO28 |
anti- FBXO32 antibody |
FNab03044 |
FN Test |
100µg |
EUR 606.3 |
|
Description: Antibody raised against FBXO32 |
anti- FBXO41 antibody |
FNab03045 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against FBXO41 |
anti- FBXO43 antibody |
FNab03046 |
FN Test |
100µg |
EUR 702 |
|
Description: Antibody raised against FBXO43 |
Lenti ORF clone of Fbxo17 (mGFP-tagged) - Mouse F-box protein 17 (Fbxo17) |
MR203902L4 |
Origene Technologies GmbH |
10 µg |
Ask for price |
FBXO17 (NM_024907) Human Recombinant Protein |
E45H31903E1 |
EnoGene |
50 ug |
EUR 552.5 |
FBXO17 (Myc-DDK-tagged)-Human F-box protein 17 (FBXO17), transcript variant 2 |
RC202158 |
Origene Technologies GmbH |
10 µg |
Ask for price |
FBXO17 (Myc-DDK-tagged)-Human F-box protein 17 (FBXO17), transcript variant 1 |
RC222996 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Fbxo17 ORF Vector (Rat) (pORF) |
ORF066996 |
ABM |
1.0 ug DNA |
EUR 607.2 |
FBXO17 ORF Vector (Human) (pORF) |
ORF003959 |
ABM |
1.0 ug DNA |
EUR 114 |
Fbxo17 ORF Vector (Mouse) (pORF) |
ORF044653 |
ABM |
1.0 ug DNA |
EUR 607.2 |
anti- FBXO2 antibody |
FNab03040 |
FN Test |
100µg |
EUR 606.3 |
|
Description: Antibody raised against FBXO2 |
anti- FBXO3 antibody |
FNab03043 |
FN Test |
100µg |
EUR 606.3 |
|
Description: Antibody raised against FBXO3 |
anti- FBXO5 antibody |
FNab03047 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against FBXO5 |
anti- FBXO6 antibody |
FNab03048 |
FN Test |
100µg |
EUR 606.3 |
|
Description: Antibody raised against FBXO6 |
anti- FBXO7 antibody |
FNab03049 |
FN Test |
100µg |
EUR 702 |
|
Description: Antibody raised against FBXO7 |
anti- FBXO8 antibody |
FNab03050 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against FBXO8 |
anti- FBXO9 antibody |
FNab03051 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against FBXO9 |
Lenti ORF clone of Fbxo17 (Myc-DDK-tagged) - Mouse F-box protein 17 (Fbxo17) |
MR203902L3 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Human FBXO17 knockout cell line |
ABC-KH5399 |
AcceGen |
1 vial |
Ask for price |
Description: Human FBXO17 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
Human FBXO17 knockdown cell line |
ABC-KD5399 |
AcceGen |
1 vial |
Ask for price |
Description: Human FBXO17 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
Human FBXO17 Protein Lysate 20ug |
IHUFBXO17PLLY20UG |
Innovative research |
each |
EUR 213 |
|
Description: Human FBXO17 Protein Lysate 20ug |
FBXO17 Peptide - N-terminal region |
MBS3242435-01mg |
MyBiosource |
0.1mg |
EUR 180 |
FBXO17 Peptide - N-terminal region |
MBS3242435-5x01mg |
MyBiosource |
5x0.1mg |
EUR 730 |
Recombinant Human FBXO17, His-tagged |
FBXO17-12786H |
Creative BioMart |
25ug |
EUR 255.2 |
Description: The protein is stored in PBS buffer at -20℃. Avoid repeated freezing and thawing cycles. |
FBXO17 Over-expression Lysate Product |
GWB-6BC062 |
GenWay Biotech |
0.1 mg |
Ask for price |
FBXO17 (NM_148169) Human Over-expression Lysate |
E45H14388-2 |
EnoGene |
each |
EUR 395 |
FBXO17 (NM_024907) Human Over-expression Lysate |
E45H12180-2 |
EnoGene |
each |
EUR 395 |
FBXO17 (NM_148169) Human Over-expression Lysate |
LS115290 |
BosterBio |
100ug |
EUR 628 |
|
Description: Transient overexpression lysate of F-box protein 17 (FBXO17), transcript variant 1 |
Lenti ORF clone of Fbxo17 (mGFP-tagged ORF) - Rat F-box protein 17 (Fbxo17), (10 ug) |
RR206465L4 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Goat anti-LMO7/FBXO20 Antibody |
MBS421148-01mg |
MyBiosource |
0.1mg |
EUR 400 |
Goat anti-LMO7/FBXO20 Antibody |
MBS421148-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1660 |
Lenti ORF particles, Fbxo17 (GFP-tagged) - Mouse F-box protein 17 (Fbxo17), 200ul, >10^7 TU/mL |
MR203902L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF clone of Fbxo17 (Myc-DDK-tagged ORF) - Rat F-box protein 17 (Fbxo17), (10 ug) |
RR206465L3 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Fbxo17 sgRNA CRISPR Lentivector set (Rat) |
K6558001 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
FBXO17 sgRNA CRISPR Lentivector set (Human) |
K0764701 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
Fbxo17 sgRNA CRISPR Lentivector set (Mouse) |
K4857601 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
Lenti ORF particles, Fbxo17 (GFP-tagged ORF) - Rat F-box protein 17 (Fbxo17), 200ul, >10^7 TU/mL |
RR206465L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, Fbxo17 (Myc-DDK-tagged) - Mouse F-box protein 17 (Fbxo17), 200ul, >10^7 TU/mL |
MR203902L3V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Fbxo17 3'UTR GFP Stable Cell Line |
TU254497 |
ABM |
1.0 ml |
Ask for price |
Fbxo17 3'UTR GFP Stable Cell Line |
TU156413 |
ABM |
1.0 ml |
Ask for price |
FBXO17 3'UTR GFP Stable Cell Line |
TU057783 |
ABM |
1.0 ml |
EUR 2799.6 |
FBXO17 Protein Vector (Rat) (pPM-C-HA) |
PV267984 |
ABM |
500 ng |
EUR 723.6 |
FBXO17 Protein Vector (Rat) (pPB-C-His) |
PV267982 |
ABM |
500 ng |
EUR 723.6 |
FBXO17 Protein Vector (Rat) (pPB-N-His) |
PV267983 |
ABM |
500 ng |
EUR 723.6 |
FBXO17 Protein Vector (Rat) (pPM-C-His) |
PV267985 |
ABM |
500 ng |
EUR 723.6 |
Lenti ORF particles, Fbxo17 (Myc-DDK-tagged ORF) - Rat F-box protein 17 (Fbxo17), 200ul, >10^7 TU/mL |
RR206465L3V |
Origene Technologies GmbH |
200 µl |
Ask for price |
FBXO17 Protein Vector (Mouse) (pPM-C-HA) |
PV178612 |
ABM |
500 ng |
EUR 723.6 |
FBXO17 Protein Vector (Human) (pPM-C-HA) |
PV015835 |
ABM |
500 ng |
EUR 394.8 |
FBXO17 Protein Vector (Mouse) (pPB-C-His) |
PV178610 |
ABM |
500 ng |
EUR 723.6 |
FBXO17 Protein Vector (Mouse) (pPB-N-His) |
PV178611 |
ABM |
500 ng |
EUR 723.6 |
FBXO17 Protein Vector (Mouse) (pPM-C-His) |
PV178613 |
ABM |
500 ng |
EUR 723.6 |
FBXO17 Protein Vector (Human) (pPB-C-His) |
PV015833 |
ABM |
500 ng |
EUR 394.8 |
FBXO17 Protein Vector (Human) (pPB-N-His) |
PV015834 |
ABM |
500 ng |
EUR 394.8 |
FBXO17 Protein Vector (Human) (pPM-C-His) |
PV015836 |
ABM |
500 ng |
EUR 394.8 |
Fbxo17 3'UTR Luciferase Stable Cell Line |
TU106413 |
ABM |
1.0 ml |
Ask for price |
FBXO17 3'UTR Luciferase Stable Cell Line |
TU007783 |
ABM |
1.0 ml |
EUR 2799.6 |
Fbxo17 3'UTR Luciferase Stable Cell Line |
TU204497 |
ABM |
1.0 ml |
Ask for price |
Fbxo17 sgRNA CRISPR Lentivector (Rat) (Target 1) |
K6558002 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Fbxo17 sgRNA CRISPR Lentivector (Rat) (Target 2) |
K6558003 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Fbxo17 sgRNA CRISPR Lentivector (Rat) (Target 3) |
K6558004 |
ABM |
1.0 ug DNA |
EUR 184.8 |
FBXO17 sgRNA CRISPR Lentivector (Human) (Target 1) |
K0764702 |
ABM |
1.0 ug DNA |
EUR 184.8 |
FBXO17 sgRNA CRISPR Lentivector (Human) (Target 2) |
K0764703 |
ABM |
1.0 ug DNA |
EUR 184.8 |
FBXO17 sgRNA CRISPR Lentivector (Human) (Target 3) |
K0764704 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Fbxo17 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
K4857602 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Fbxo17 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
K4857603 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Fbxo17 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
K4857604 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Mouse monoclonal antibody Anti-Human FBXO18 |
MBS120373-01mg |
MyBiosource |
0.1mg |
EUR 470 |
Mouse monoclonal antibody Anti-Human FBXO18 |
MBS120373-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2080 |
Rat F-Box Protein 17 (FBXO17) ELISA Kit |
abx523611-96tests |
Abbexa |
96 tests |
EUR 687.5 |
Human F-Box Protein 17 (FBXO17) ELISA Kit |
abx387316-96tests |
Abbexa |
96 tests |
EUR 687.5 |
|
Lenti ORF particles, FBXO17 (mGFP-tagged) - Human F-box protein 17 (FBXO17), transcript variant 2, 200ul, >10^7 TU/mL |
RC202158L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, FBXO17 (mGFP-tagged) - Human F-box protein 17 (FBXO17), transcript variant 1, 200ul, >10^7 TU/mL |
RC222996L2V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, FBXO17 (mGFP-tagged) - Human F-box protein 17 (FBXO17), transcript variant 1, 200ul, >10^7 TU/mL |
RC222996L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Recombinant Rat F-box only protein 17 (Fbxo17) |
MBS1485150-002mgBaculovirus |
MyBiosource |
0.02mg(Baculovirus) |
EUR 1130 |
Recombinant Rat F-box only protein 17 (Fbxo17) |
MBS1485150-002mgEColi |
MyBiosource |
0.02mg(E-Coli) |
EUR 760 |
Recombinant Rat F-box only protein 17 (Fbxo17) |
MBS1485150-002mgYeast |
MyBiosource |
0.02mg(Yeast) |
EUR 920 |
Recombinant Rat F-box only protein 17 (Fbxo17) |
MBS1485150-01mgEColi |
MyBiosource |
0.1mg(E-Coli) |
EUR 915 |
Recombinant Rat F-box only protein 17 (Fbxo17) |
MBS1485150-01mgYeast |
MyBiosource |
0.1mg(Yeast) |
EUR 1080 |
Recombinant Human F-box only protein 17 (FBXO17) |
MBS1476384-002mgBaculovirus |
MyBiosource |
0.02mg(Baculovirus) |
EUR 1160 |
Recombinant Human F-box only protein 17 (FBXO17) |
MBS1476384-002mgEColi |
MyBiosource |
0.02mg(E-Coli) |
EUR 795 |
Recombinant Human F-box only protein 17 (FBXO17) |
MBS1476384-002mgYeast |
MyBiosource |
0.02mg(Yeast) |
EUR 945 |
Recombinant Human F-box only protein 17 (FBXO17) |
MBS1476384-01mgEColi |
MyBiosource |
0.1mg(E-Coli) |
EUR 955 |
Recombinant Human F-box only protein 17 (FBXO17) |
MBS1476384-01mgYeast |
MyBiosource |
0.1mg(Yeast) |
EUR 1110 |
Recombinant Mouse F-box only protein 17 (Fbxo17) |
MBS1457891-002mgBaculovirus |
MyBiosource |
0.02mg(Baculovirus) |
EUR 1165 |
Recombinant Mouse F-box only protein 17 (Fbxo17) |
MBS1457891-002mgEColi |
MyBiosource |
0.02mg(E-Coli) |
EUR 805 |
Recombinant Mouse F-box only protein 17 (Fbxo17) |
MBS1457891-002mgYeast |
MyBiosource |
0.02mg(Yeast) |
EUR 955 |
Recombinant Mouse F-box only protein 17 (Fbxo17) |
MBS1457891-01mgEColi |
MyBiosource |
0.1mg(E-Coli) |
EUR 965 |
Recombinant Mouse F-box only protein 17 (Fbxo17) |
MBS1457891-01mgYeast |
MyBiosource |
0.1mg(Yeast) |
EUR 1120 |
Anti-F-box only protein 4 FBXO4 Antibody |
A08044 |
BosterBio |
100uL |
EUR 599 |
|
Description: Boster Bio Anti-F-box only protein 4 FBXO4 Antibody (Catalog # A08044). Tested in IF, WB applications. This antibody reacts with Human, Mouse. |
Recombinant Rat FBXO17 Protein, His (Fc)-Avi-tagged |
FBXO17-1946R |
Creative BioMart |
50ug |
EUR 2398.4 |
|
Description: For long term storage, aliquot and store at -20 to -80 centigrade. Avoid repeated freezing and thawing cycles. |
Lenti ORF particles, FBXO17 (Myc-DDK tagged) - Human F-box protein 17 (FBXO17), transcript variant 2, 200ul, >10^7 TU/mL |
RC202158L3V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, FBXO17 (Myc-DDK tagged) - Human F-box protein 17 (FBXO17), transcript variant 1, 200ul, >10^7 TU/mL |
RC222996L1V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, FBXO17 (Myc-DDK tagged) - Human F-box protein 17 (FBXO17), transcript variant 1, 200ul, >10^7 TU/mL |
RC222996L3V |
Origene Technologies GmbH |
200 µl |
Ask for price |
FBXO17 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV665293 |
ABM |
1.0 ug DNA |
EUR 616.8 |
FBXO17 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV665297 |
ABM |
1.0 ug DNA |
EUR 616.8 |
Rat F box only protein 17(FBXO17) ELISA kit |
E01A13263 |
BlueGene |
96T |
EUR 700 |
Description: ELISA |
Rat F box only protein 17(FBXO17) ELISA kit |
E02F0279-192T |
BlueGene |
192 tests |
EUR 1524 |
|
Description: A competitive ELISA for quantitative measurement of Rat F box only protein 17(FBXO17) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Rat F box only protein 17(FBXO17) ELISA kit |
E02F0279-48 |
BlueGene |
1 plate of 48 wells |
EUR 624 |
|
Description: A competitive ELISA for quantitative measurement of Rat F box only protein 17(FBXO17) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Rat F box only protein 17(FBXO17) ELISA kit |
E02F0279-48wellsplate |
BlueGene |
48 wells plate |
EUR 280 |
Rat F box only protein 17(FBXO17) ELISA kit |
E02F0279-96 |
BlueGene |
1 plate of 96 wells |
EUR 822 |
|
Description: A competitive ELISA for quantitative measurement of Rat F box only protein 17(FBXO17) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Rat F box only protein 17(FBXO17) ELISA kit |
E02F0279-96wellsplate |
BlueGene |
96 wells plate |
EUR 405 |
Dog F box only protein 17(FBXO17) ELISA kit |
E08F0279-192T |
BlueGene |
192 tests |
EUR 1524 |
|
Description: A competitive ELISA for quantitative measurement of Canine F box only protein 17(FBXO17) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Dog F box only protein 17(FBXO17) ELISA kit |
E08F0279-48 |
BlueGene |
1 plate of 48 wells |
EUR 624 |
|
Description: A competitive ELISA for quantitative measurement of Canine F box only protein 17(FBXO17) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Dog F box only protein 17(FBXO17) ELISA kit |
E08F0279-96 |
BlueGene |
1 plate of 96 wells |
EUR 822 |
|
Description: A competitive ELISA for quantitative measurement of Canine F box only protein 17(FBXO17) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Pig F box only protein 17(FBXO17) ELISA kit |
E07F0279-192T |
BlueGene |
192 tests |
EUR 1524 |
|
Description: A competitive ELISA for quantitative measurement of Porcine F box only protein 17(FBXO17) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Furthermore, the dual-luciferase reporter gene test revealed that the area 3′-untranslated (UTR) endothelin A receptor (Ednra) MRNA contains a binding site for MMU-MIR-1929-3P. Collectively, our data shows that MCMV infection can increase blood pressure and reduce MMU-MIR-1929-3P expression in C57BL / 6. In addition, we find that MMU-MIR-1929-3P targets 3 ‘UTR from MRNA Ednra. Conclusion This new regulation axis can help develop a new approach to clinical prevention and control eh.